Download App

Log in to access Online Inquiry
Company Overview More
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
CEO: Castagna Pharm.D., Michael E.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > MNKD MannKind > Detailed Quotes

MNKD MannKind

4.170+0.490+13.32%
Close 05/23 19:28 ET
4.350+0.18+4.32%
Post Mkt Price 05/23 19:37 ET
High
4.770
Open
3.730
Turnover
105.89M
Low
3.570
Pre Close
3.680
Volume
25.42M
Market Cap
1.05B
P/E(TTM)
Loss
52wk High
5.530
Shares
252.57M
P/E(Static)
Loss
52wk Low
2.490
Float Cap
985.55M
Bid/Ask %
61.64%
Historical High
121.550
Shs Float
236.34M
Volume Ratio
4.29
Historical Low
0.666
Dividend TTM
--
Div Yield TTM
--
P/B
-4.54
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
10.76%
Amplitude
32.61%
Avg Price
4.165
Lot Size
1
Float Cap
985.55M
Bid/Ask %
61.64%
Historical High
121.550
Shs Float
236.34M
Volume Ratio
4.29
Historical Low
0.666
Dividend TTM
--
P/B
-4.54
Dividend LFY
--
Turnover Ratio
10.76%
Amplitude
32.61%
Avg Price
4.165
Lot Size
1
Price Forecast

No Data

News

Comment